The U.S. insulin market can be segmented by insulin type, yielding four segments: long-acting insulin, rapid-acting insulin, premixed insulin and human insulin. In 2016, the largest segment in the total insulin market was long-acting insulin. Patent expirations and the introduction of new products will lead to higher unit sales growth in this segment, relative to the rapid-acting insulin, premixed insulin and human insulin segments. Combined with steady appreciation of ASP, it is projected that long-acting insulin will be the fastest growing segment in the total insulin market over the forecast period. In terms of volume market share, premixed insulin represents the smallest portion of the total insulin market as well. It is expected that this trend will continue and ASP appreciation will follow the general upward trend of the total insulin market over the forecast period.
Insulin is a hormone that causes glucose uptake from the blood through the cells of the liver, muscle and fat tissue to be stored as glycogen in the liver and muscle. Type 1 diabetics’ immune systems destroy pancreatic beta cells: the only cells that can make insulin. The body therefore fails to produce insulin and cannot naturally convert food into energy. Type 2 diabetics have a resistance to insulin, and cells are not able to use the insulin present in the body. The need for insulin increases to the point that the pancreas can no longer produce it. Insulin is therefore a mode of treating both type 1 and type 2 diabetes.